Ivana Magovčević-Liebisch has been President and CEO of Draig Therapeutics, a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, since November 2025.
She is a member of the Board of Directors for Acrivon Therapeutics, a publicly traded biotech focused on precision-based cancer therapeutics, and Quanterix Corporation, a publicly traded life sciences company focused on ultra-sensitive biomarker-based diagnostics.
She was Chairwoman of the Board of Directors for Absci Corporation (Nasdaq: ABSI), a biotech with a proprietary biologic discovery platform. She led the board through Absci's transition from a private organisation through its IPO and into a publicly traded company. She was also a member of the Board of Directors and Compensation and Audit Committees for Aeglea Biotherapeutics (now Spyre Therapeutics), a public biotech focused on inflammatory bowel disease, and has held board positions for Applied Genetic Technologies Corporation, focused on gene therapy for rare diseases, and Alivio Pharmaceuticals, a private biotech focusing on inflammatory diseases.
She joins Draig having most recently served as President and CEO of Vigil Neuroscience, a company she founded, built and led until its acquisition by Sanofi in August 2025. Under her leadership, Vigil raised more than $350 million and advanced its lead pipeline candidates into clinical development, including the first clinical-stage small molecule TREM2 agonist for the potential treatment of Alzheimer's disease.
Prior to Vigil, she was EVP and Chief Business Officer at Ipsen, where she was responsible for fuelling the pipeline through external innovation, leading the External Innovation, Business Development, and Alliance Management functions. Before Ipsen, she was EVP, Chief Strategy and Corporate Development Officer at Axcella Health, and SVP and Head of Global Business Development for the specialty drug business at Teva Pharmaceutical Industries Ltd. At Teva, she executed approximately 15 transactions across different therapeutic areas and modalities, with an overall deal value of approximately $5 billion, resulting in 7 marketed products.
Prior to Teva, she held multiple pivotal roles at Dyax (acquired by Shire, now Takeda), including EVP, Chief Operating Officer, Chief Business Officer and General Counsel. She built out the commercial infrastructure for the company's first approved drug, launched a successful IP licensing programme generating over $400 million, and executed equity financings and corporate partnering agreements.
Ivana holds a Ph.D. in Genetics from Harvard University and received her J.D. in High Technology Law from Suffolk University Law School. She graduated from Wheaton College with a B.A. in Biology and Chemistry.
In 2018, Ivana was the winner of the Women Entrepreneurs in Science and Technology Leadership Award.
CEO Clinics are an intimate forum for confidential exchange on a given topic and therefore limited to 6-8 Members.
If you are interested in joining this Clinic, you must RSVP here on the platform.
In the event that more than 8 people sign up, we will allocate places one week before the event.